NASDAQ:CBPO - China Biologic Products Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$95.08 +0.59 (+0.62 %)
(As of 08/15/2018 02:57 AM ET)
Previous Close$94.49
Today's Range$93.43 - $95.50
52-Week Range$71.85 - $107.44
Volume368,200 shs
Average Volume294,835 shs
Market Capitalization$3.09 billion
P/E Ratio19.07
Dividend YieldN/A
Beta1.36
China Biologic Products logoChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111

Debt

Debt-to-Equity RatioN/A
Current Ratio6.25
Quick Ratio4.27

Price-To-Earnings

Trailing P/E Ratio19.07
Forward P/E Ratio22.37
P/E Growth1.69

Sales & Book Value

Annual Sales$370.41 million
Price / Sales8.50
Cash Flow$4.7374 per share
Price / Cash20.07
Book Value$20.05 per share
Price / Book4.74

Profitability

EPS (Most Recent Fiscal Year)$4.95
Net Income$67.94 million
Net Margins15.89%
Return on Equity14.00%
Return on Assets12.16%

Miscellaneous

Employees1,799
Outstanding Shares33,130,000
Market Cap$3.09 billion

China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) issued its quarterly earnings results on Friday, August, 3rd. The biopharmaceutical company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.26 by $0.09. The biopharmaceutical company had revenue of $120.40 million for the quarter, compared to analysts' expectations of $116.21 million. China Biologic Products had a net margin of 15.89% and a return on equity of 14.00%. China Biologic Products's revenue for the quarter was up 34.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.35 EPS. View China Biologic Products' Earnings History.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for China Biologic Products.

What price target have analysts set for CBPO?

3 brokerages have issued 1 year price targets for China Biologic Products' stock. Their forecasts range from $97.00 to $105.00. On average, they anticipate China Biologic Products' share price to reach $101.00 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for China Biologic Products.

What is the consensus analysts' recommendation for China Biologic Products?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.

Are investors shorting China Biologic Products?

China Biologic Products saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 1,235,909 shares, a decline of 31.4% from the June 15th total of 1,801,541 shares. Based on an average trading volume of 589,014 shares, the days-to-cover ratio is presently 2.1 days. Currently, 5.4% of the shares of the stock are short sold. View China Biologic Products' Current Options Chain.

Who are some of China Biologic Products' key competitors?

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the folowing people:
  • Mr. Zhijun Tong, Acting CEO & Director (Age 58)
  • Mr. Ming Yang, Chief Financial Officer (Age 46)
  • Mr. Ming Yin, Sr. Corp. VP (Age 40)
  • Ms. Zhijing Liu, Corp. VP (Age 64)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53)

Has China Biologic Products been receiving favorable news coverage?

Headlines about CBPO stock have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. China Biologic Products earned a news and rumor sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.69 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for China Biologic Products.

Who are China Biologic Products' major shareholders?

China Biologic Products' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.07%), Bank of America Corp DE (1.97%), BlackRock Inc. (1.57%), Macquarie Group Ltd. (1.03%), Wasatch Advisors Inc. (0.86%) and Bank of New York Mellon Corp (0.86%). Company insiders that own China Biologic Products stock include David Gao, Ming Yang, Sean Shao, Wenfang Liu and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products.

Which institutional investors are selling China Biologic Products stock?

CBPO stock was sold by a variety of institutional investors in the last quarter, including Vontobel Asset Management Inc., BlackRock Inc., Bank of New York Mellon Corp, Macquarie Group Ltd., Russell Investments Group Ltd., GSA Capital Partners LLP, Jupiter Asset Management Ltd. and Sei Investments Co.. View Insider Buying and Selling for China Biologic Products.

Which institutional investors are buying China Biologic Products stock?

CBPO stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Point72 Hong Kong Ltd, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, First Trust Advisors LP, Van Berkom & Associates Inc., Point72 Asset Management L.P., Renaissance Technologies LLC and Baillie Gifford & Co.. View Insider Buying and Selling for China Biologic Products.

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $95.08.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $3.09 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,799 workers across the globe.

How can I contact China Biologic Products?

China Biologic Products' mailing address is JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD 18TH FLOOR, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]


MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  547
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.